Skip to main content
OpenTrials
Completed

NCT Number: NCT00232232

Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia

The purpose of this study is to investigate whether fish oils may be of benefit to patients with certain heart rhythm disturbances called atrial fibrillation and atrial flutter.

Atrial fibrillation and atrial flutter are two heart conditions that can be successfully treated in the hospital by an ablation (in the case of atrial flutter) or a cardioversion (in the case of atrial fibrillation). Ablation involves the application of high frequency energy waves to a particular spot in the heart. Cardioversion involves resetting the heart back to a normal rhythm with the use of an electric current.

Fish oil supplements may be of benefit to patients with heart problems. Recent evidence suggests that fish oils may benefit those with rhythm disturbances.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Atrial Flutter Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Royal Melbourne Hospital

Melbourne, Victoria, 3050, Australia

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Chronic atrial flutter requiring radiofrequency ablation.
  • Chronic atrial fibrillation requiring internal cardioversion.

Exclusion criteria

  • Sinus rhythm.
  • Pregnancy.
  • Patients > 80 years and < 18 years of age

Treatment and study plan

Fish oil

Drug

Primary outcomes

  1. The extent of left atrial stunning in fish oil group compared to control after reversion of atrial arrhythmias to sinus rhythm.

    Time frame: 18 months

Other outcomes

  1. Adverse events related to fish oil ingestion.

    Time frame: 18 months

    Tolerability, mortality.

Sponsors and collaborators

Lead sponsor

Melbourne Health

Other

Registry information

Important dates

Study start
2003
Primary completion
2013
Study completion
2013
First posted
Oct 4, 2005
Registry last updated
May 12, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.